Abstract: Aminoketone derivative compounds containing a heterocyclic ring bonded to an aminoketone moiety and useful as effective ingredients of centrally acting muscle relaxants and pollakiurea curing agents.(+)3-phenyl-5-[2-(1-pyrrolidinylmethyl)butyryl] isoxazole, which has a more remarkable central muscle relaxant action as compared with its racemic modification, can be effectively separated from the racemic modification using optically active 10-camphorsulfonic acid as the agent for the optical resolution.

Abstract: Aminoketone derivative compounds containing a heterocyclic ring bonded to an aminoketone moiety and useful as effective ingredients of centrally acting muscle relaxants and pollakiurea curing agents.(+)3-phenyl-5-[2-(1-pyrrolidinylmethyl)butyryl]isoxazole, which has a more remarkable central muscle relaxant action as compared with its racemic modification, can be effectively separated from the racemic modification using optically active 10-camphorsulfonic acid as the agent for the optical resolution.

Abstract: Aminoketone derivative compounds containing a heterocyclic ring bonded to an aminoketone moiety and useful as effective ingredients of centrally acting muscle relaxants and pollakiurea curing agents.(+)3-phenyl-5-[2-(1-pyrrolidinylmethyl)butyryl]isoxazole, which has a more remarkable central muscle relaxant action as compared with its racemic modification, can be effectively separated from the racemic modification using optically active 10-camphorsulfonic acid as the agent for the optical resolution.

Abstract: The present invention relates to a novel (-)-2-pyrazoline compound and therapeutic agents containing the same as an effective ingredient; furthermore, it relates to a method for optically resolving 1-(3-pyridylcarbonyl)-5-methyl-2-pyrazoline.

Abstract: The present invention relates to a novel (-)-2-pyrazoline compound and therapeutic agents containing the same as an effective ingredient; furthermore, it relates to a method for optically resolving 1-(3-pyridylcarbonyl)-5-methyl-2-pyrazoline.

Abstract: The isoquinoline derivatives represented by the following general formula (I) are useful as cardiotonics having high cardiotonic activity and low toxicity: ##STR1## where R.sub.1 represents a lower C.sub.1 -C.sub.4 alkyl group or cyclopropyl group,R.sub.2 represents formyl group, lower C.sub.1 -C.sub.4 alkanoyl group and benzoyl group, lower C.sub.1 -C.sub.4 alkyl group, lower C.sub.1 -C.sub.4 alkenyl group, lower C.sub.1 -C.sub.4 hydroxy substituted alkyl group, C.sub.1 -C.sub.4 perfluoroalkyl group andR.sub.3 represents 4-pyridyl group or 2-pyridyl group respectively,and the therapeutically acceptable salts thereof are also useful as cardiotonics.

Abstract: Disclosed are 2-thiazol derivatives having the general formula ##STR1## where R.sub.1 and R.sub.2 independently represent lower alkyl radicals having 1 to 4 carbon atoms and X represents a lower alkyl radical, a lower alkoxy radical, a lower alkoxycarbonyl radical, a halogenoalkoxy radical, a radical of the formula ##STR2## or a radical of the formula ##STR3## Also disclosed are a process for preparing the derivatives and pharmaceutical compositions having immunomodulatory activity which comprise the derivatives as the active ingredient.

Abstract: Disclosed are uracil derivatives having the general formula ##STR1## where R represents a hydrogen atom or an alkyl radical having 1 to 4 carbon atoms. Also disclosed are a process for preparing these compounds and pharmaceutical compositions having immunomodulatory activity which comprise these compounds as the active ingredient.

Abstract: The present invention provides new chemical compounds, N-(4-phenyl-2-thiazolyl)carbamate derivatives, a process for preparing the same and pharmaceutical compositions containing the carbamate derivatives. More particularly, the present invention provides N-(4-phenyl-2-thiazolyl)carbamate derivatives which have immuno-modulating activity and are thus effective against immunodiseases such as chronic rheumatoid arthritis and also useful against viral diseases or for the immunotherapy of cancers with low toxicity.

Abstract: The present invention provides new thiazole compounds possessing immuno-modulating activity, i.e. thiazole compounds of the general formula (1): ##STR1## wherein R.sub.1 stands for a hydrogen or halogen atom or a lower alkyl, lower alkoxy, substituted or unsubstituted phenoxy, nitro or cyano group, R.sub.2 for a hydrogen atom or a lower alkyl or lower alkylthio group, and R for an .alpha.-halogenoalkyl group or the grouping: ##STR2## a process for preparing same and pharmaceutical compositions containing the thiazole compounds.

Abstract: The present invention provides thiazolyl derivatives as new chemical substance represented by the general formula: ##STR1## wherein R.sup.1 stands for a lower alkyl group or a substituted or unsubstituted phenyl group, R.sup.2 for a hydrogen atom, a lower alkyl, lower alkoxy or lower alkylthio group, and R.sup.3 for a pyridyl or iso-oxazolyl group or a grouping of the general formula: ##STR2## processes for preparing same and pharmaceutical compositions containing the thiazolyl derivatives. More particularly, the present invention provides new thiazolyl derivatives which possess immuno-modulating activity and are thus therapeutically effective against immunodiseases such as chronic rheumatoid arthritis and also useful against viral diseases or for the immunotherapy of cancers and possess properties desirous as medicines with a slight toxicity, processes for preparing same and pharmaceutical compositions containing the new substance.